MA29044B1 - Formulations inmunotherapeutiques a capacite de neutralisation de l'interleukine-2 - Google Patents

Formulations inmunotherapeutiques a capacite de neutralisation de l'interleukine-2

Info

Publication number
MA29044B1
MA29044B1 MA29960A MA29960A MA29044B1 MA 29044 B1 MA29044 B1 MA 29044B1 MA 29960 A MA29960 A MA 29960A MA 29960 A MA29960 A MA 29960A MA 29044 B1 MA29044 B1 MA 29044B1
Authority
MA
Morocco
Prior art keywords
inmunotherapeutic
interleukin
formulations
neutralization capacity
neutralization
Prior art date
Application number
MA29960A
Other languages
English (en)
Inventor
Casimiro Jose Enrique Montero
Sarduy Livan Bladimir Alonso
Rodriguez Rolando Perez
Davila Agustin Bienvenido Lage
Original Assignee
Ct De Inmunolgia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Inmunolgia Molecular filed Critical Ct De Inmunolgia Molecular
Publication of MA29044B1 publication Critical patent/MA29044B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA29960A 2004-11-16 2007-05-30 Formulations inmunotherapeutiques a capacite de neutralisation de l'interleukine-2 MA29044B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20040261A CU23297A1 (es) 2004-11-16 2004-11-16 Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer

Publications (1)

Publication Number Publication Date
MA29044B1 true MA29044B1 (fr) 2007-11-01

Family

ID=40122436

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29960A MA29044B1 (fr) 2004-11-16 2007-05-30 Formulations inmunotherapeutiques a capacite de neutralisation de l'interleukine-2

Country Status (25)

Country Link
US (1) US20090274647A1 (fr)
EP (2) EP1829893B1 (fr)
JP (1) JP5227028B2 (fr)
KR (1) KR101240457B1 (fr)
CN (1) CN101061136B (fr)
AR (1) AR051494A1 (fr)
AT (1) ATE525393T1 (fr)
AU (1) AU2005306186B2 (fr)
BR (1) BRPI0518007A (fr)
CA (1) CA2588573C (fr)
CR (1) CR9097A (fr)
CU (1) CU23297A1 (fr)
EA (1) EA012072B1 (fr)
GE (1) GEP20105039B (fr)
HK (1) HK1113374A1 (fr)
MA (1) MA29044B1 (fr)
MX (1) MX2007005808A (fr)
MY (1) MY162106A (fr)
PE (1) PE20061172A1 (fr)
SG (1) SG122897A1 (fr)
TN (1) TNSN07187A1 (fr)
TR (1) TR200704213T2 (fr)
TW (1) TWI433853B (fr)
WO (1) WO2006053508A1 (fr)
ZA (1) ZA200703528B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542592A (ja) * 2006-07-06 2009-12-03 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
WO2015162124A1 (fr) * 2014-04-22 2015-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes de diagnostic d'une maladie auto-immune
US10138298B2 (en) 2015-10-23 2018-11-27 The Regents Of The University Of California Anti-IL-2 antibodies and compositions and uses thereof
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
CU20210021A7 (es) * 2021-03-30 2022-11-07 Ct Inmunologia Molecular Composicones vacunales depletantes de factores de crecimiento hematopoyéticos para el tratamiento de enfermedades inflamatorias

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5939832A (ja) * 1982-08-28 1984-03-05 Ajinomoto Co Inc モノクロ−ナル抗体ならびにその製法、使用法
JPS59116231A (ja) * 1982-12-13 1984-07-05 スロ−ン−ケツタリング・インステイテユ−ト・フオ−・キヤンサ−・リサ−チ 抗−インタ−ロイキン−２単クロ−ン抗体
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
HUT60768A (en) * 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
US5830452A (en) 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JPH10147952A (ja) 1996-11-18 1998-06-02 Komatsu Ltd ブルドーザのドージング装置
US20040156824A1 (en) * 1996-12-23 2004-08-12 Epstein Alan L. Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
CA2219961C (fr) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeabilite ameliorant les peptides de l'interleukine-2 chez l'humain et les immunoconjugues
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
US6168785B1 (en) * 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
CN1192796C (zh) * 1999-02-12 2005-03-16 斯克里普斯研究学院 联合应用抗血管生成和免疫治疗以治疗肿瘤和转移的方法
WO2001080889A1 (fr) * 2000-04-26 2001-11-01 National Jewish Medical And Research Center Regulation de la reponse des lymphocytes t et produit a cet effet
CU23011A1 (es) * 2000-11-03 2004-12-17 Ct Ingenieria Genetica Biotech Método de obtención de estructuras antigénicas quemétodo de obtención de estructuras antigénicas que potencian la reactividad cruzada específica y su potencian la reactividad cruzada específica y su uso en formulaciones uso en formulaciones
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
CU22979A1 (es) * 2000-12-08 2004-09-09 Centro Inmunologia Molecular Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
CU22999A1 (es) * 2001-12-04 2004-10-12 Centro Inmunologia Molecular Método de tratamiento de enfermedades malignas e infecciosas crónicas
WO2002087304A2 (fr) * 2001-04-30 2002-11-07 Frohnhofen, Wilfried Peptides d'interleukine-2 et peptides et dimeres peptidiques derives d'interleukine-2
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
ITMI20012527A1 (it) 2001-11-30 2003-05-30 Unihart Corp Proteine di fusione contenenti peptidi tlp
DK1461073T3 (da) * 2001-11-30 2010-03-29 Us Gov Health & Human Serv Peptidagonister til prostataspecifikt antigen og anvendelser heraf
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
WO2005007121A2 (fr) * 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Polypeptides de l'interleukine-2(il-2) mutante

Also Published As

Publication number Publication date
EA012072B1 (ru) 2009-08-28
GEP20105039B (en) 2010-07-12
TNSN07187A1 (en) 2008-11-21
AU2005306186B2 (en) 2012-05-31
MY162106A (en) 2017-05-31
CN101061136A (zh) 2007-10-24
AR051494A1 (es) 2007-01-17
CU23297A1 (es) 2008-07-24
CN101061136B (zh) 2012-12-05
EP1829893B1 (fr) 2011-09-21
CR9097A (es) 2007-08-28
TWI433853B (zh) 2014-04-11
JP5227028B2 (ja) 2013-07-03
KR20070084025A (ko) 2007-08-24
SG122897A1 (en) 2006-06-29
CA2588573A1 (fr) 2006-05-26
JP2008526686A (ja) 2008-07-24
EP2112160A3 (fr) 2010-01-13
EA200701071A1 (ru) 2007-12-28
KR101240457B1 (ko) 2013-03-08
AU2005306186A1 (en) 2006-05-26
EP2112160B1 (fr) 2015-07-08
ATE525393T1 (de) 2011-10-15
EP2112160A2 (fr) 2009-10-28
BRPI0518007A (pt) 2008-10-21
TR200704213T2 (tr) 2007-08-21
EP1829893A1 (fr) 2007-09-05
TW200631591A (en) 2006-09-16
CA2588573C (fr) 2013-12-31
HK1113374A1 (en) 2008-10-03
MX2007005808A (es) 2007-07-20
WO2006053508A1 (fr) 2006-05-26
ZA200703528B (en) 2008-06-25
PE20061172A1 (es) 2006-12-16
US20090274647A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
DK1506781T3 (da) Vaginalplejesammensætning
DE602005015466D1 (de) Antivirale 4'-azidonucleoside
ATE370714T1 (de) Geformtes tampon
DE60312780D1 (de) Wegwerfwindel
IS8309A (is) Lyfjablöndur
FR2840811B1 (fr) Materiau de rechargement osseux
AR028410A1 (es) Fabricacion de baterias
MA29044B1 (fr) Formulations inmunotherapeutiques a capacite de neutralisation de l'interleukine-2
DE60111484D1 (de) Flexible Batteriestruktur
DE50305758D1 (de) Mikroendoskop
IS6933A (is) Veirueyðandi samsetningar
DE60301432D1 (de) Bewegbares Spielzeug
DE60333672D1 (de) Sprühbare ölartige formulierungen
FR2850146B1 (fr) Corps de friction
ATA292002A (de) Verdrängungskörper
FR2853380B1 (fr) Articulation elastique
FR2856916B1 (fr) Prothese unicompartimentale de genou
ITMI20031067A0 (it) Asta estendibile ad elevata flessibilita'
UA9419S (uk) Інтер`єр піцерії «new-york-street-pizza»
UA11746S (uk) Вимикач електричний серії «mimoza»
FR2857288B1 (fr) Ventouse de prehension
SE0001668D0 (sv) Flexible batteries
UA10900S (uk) Іграшка сувенірна «мітла»
ES1055950Y (es) Escobilla de retrete con punta desechable
UA10027S (uk) Іграшка «ежик»